<qa>  What is the name of the study cohort?The objectives of this project are to investigate the safety and toxicity of the combination of raloxifene, a selective estrogen receptor modulator SERM, with exemestane, a new steroidal aromatase inhibitor, in postmenopausal women with a history of breast cancer who have no clinical evidence of disease. The study cohort will consist of postmenopausal women with a history of AJCC Stage 0, I, II, or III breast cancer after completion of all planned adjuvant therapy. The study cohort is limited to patients who have not already received anti-estrogen therapy as part of post-operative adjuvant treatment. Patients with a history of invasive ER- andor PR-positive breast cancer are eligible only if they have not received an anti-estrogen as part of adjuvant therapy, and they are at least 2 years from the time of their primary surgery. 